Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

A microscale double labelling of GAG oligosaccharides compatible with enzymatic treatment and mass spectrometry.

Przybylski C, Bonnet V, Vivès RR.

Chem Commun (Camb). 2019 Apr 4;55(29):4182-4185. doi: 10.1039/c9cc00254e.

PMID:
30892311
2.

Substrate binding mode and catalytic mechanism of human heparan sulfate d-glucuronyl C5 epimerase.

Debarnot C, Monneau YR, Roig-Zamboni V, Delauzun V, Le Narvor C, Richard E, Hénault J, Goulet A, Fadel F, Vivès RR, Priem B, Bonnaffé D, Lortat-Jacob H, Bourne Y.

Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):6760-6765. doi: 10.1073/pnas.1818333116. Epub 2019 Mar 14.

PMID:
30872481
3.

Heparan sulfate in chronic kidney diseases: Exploring the role of 3-O-sulfation.

Ferreras L, Moles A, Situmorang GR, El Masri R, Wilson IL, Cooke K, Thompson E, Kusche-Gullberg M, Vivès RR, Sheerin NS, Ali S.

Biochim Biophys Acta Gen Subj. 2019 May;1863(5):839-848. doi: 10.1016/j.bbagen.2019.02.009. Epub 2019 Feb 19.

PMID:
30794825
4.

Expression and purification of recombinant extracellular sulfatase HSulf-2 allows deciphering of enzyme sub-domain coordinated role for the binding and 6-O-desulfation of heparan sulfate.

Seffouh A, El Masri R, Makshakova O, Gout E, Hassoun ZEO, Andrieu JP, Lortat-Jacob H, Vivès RR.

Cell Mol Life Sci. 2019 May;76(9):1807-1819. doi: 10.1007/s00018-019-03027-2. Epub 2019 Feb 20.

PMID:
30788513
5.

Mass spectrometry analysis of the human endosulfatase Hsulf-2.

Seffouh I, Przybylski C, Seffouh A, El Masri R, Vivès RR, Gonnet F, Daniel R.

Biochem Biophys Rep. 2019 Feb 7;18:100617. doi: 10.1016/j.bbrep.2019.01.010. eCollection 2019 Jul.

6.

A proliferation-inducing ligand-mediated anti-inflammatory response of astrocytes in multiple sclerosis.

Baert L, Benkhoucha M, Popa N, Ahmed MC, Manfroi B, Boutonnat J, Sturm N, Raguenez G, Tessier M, Casez O, Marignier R, Ahmadi M, Broisat A, Ghezzi C, Rivat C, Sonrier C, Hahne M, Baeten D, Vives RR, Lortat-Jacob H, Marche PN, Schneider P, Lassmann HP, Boucraut J, Lalive PH, Huard B.

Ann Neurol. 2019 Mar;85(3):406-420. doi: 10.1002/ana.25415. Epub 2019 Feb 4.

PMID:
30635946
7.

Genetic and enzymatic characterization of 3-O-sulfotransferase SNPs associated with Plasmodium falciparum parasitaemia.

Nguyen NT, Vivès RR, Torres M, Delauzun V, Saesen E, Roig-Zamboni V, Lortat-Jacob H, Rihet P, Bourne Y.

Glycobiology. 2018 Jul 1;28(7):534-541. doi: 10.1093/glycob/cwy038.

8.

Solution structure of CXCL13 and heparan sulfate binding show that GAG binding site and cellular signalling rely on distinct domains.

Monneau YR, Luo L, Sankaranarayanan NV, Nagarajan B, Vivès RR, Baleux F, Desai UR, Arenzana-Seidedos F, Lortat-Jacob H.

Open Biol. 2017 Oct;7(10). pii: 170133. doi: 10.1098/rsob.170133.

9.

A jasmonic acid derivative improves skin healing and induces changes in proteoglycan expression and glycosaminoglycan structure.

Henriet E, Jäger S, Tran C, Bastien P, Michelet JF, Minondo AM, Formanek F, Dalko-Csiba M, Lortat-Jacob H, Breton L, Vivès RR.

Biochim Biophys Acta Gen Subj. 2017 Sep;1861(9):2250-2260. doi: 10.1016/j.bbagen.2017.06.006. Epub 2017 Jun 8.

PMID:
28602514
10.

High sodium diet converts renal proteoglycans into pro-inflammatory mediators in rats.

Hijmans RS, Shrestha P, Sarpong KA, Yazdani S, El Masri R, de Jong WHA, Navis G, Vivès RR, van den Born J.

PLoS One. 2017 Jun 8;12(6):e0178940. doi: 10.1371/journal.pone.0178940. eCollection 2017.

11.

The "in and out" of glucosamine 6-O-sulfation: the 6th sense of heparan sulfate.

El Masri R, Seffouh A, Lortat-Jacob H, Vivès RR.

Glycoconj J. 2017 Jun;34(3):285-298. doi: 10.1007/s10719-016-9736-5. Epub 2016 Nov 3. Review.

PMID:
27812771
12.

Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma.

Heidari-Hamedani G, Vivès RR, Seffouh A, Afratis NA, Oosterhof A, van Kuppevelt TH, Karamanos NK, Metintas M, Hjerpe A, Dobra K, Szatmári T.

Cell Signal. 2015 Oct;27(10):2054-67. doi: 10.1016/j.cellsig.2015.07.017. Epub 2015 Jul 23. Erratum in: Cell Signal. 2015 Dec;27(12):2599-601.

13.

Heparan sulfate-dependent enhancement of henipavirus infection.

Mathieu C, Dhondt KP, Châlons M, Mély S, Raoul H, Negre D, Cosset FL, Gerlier D, Vivès RR, Horvat B.

MBio. 2015 Mar 10;6(2):e02427. doi: 10.1128/mBio.02427-14.

14.

Langerin-heparin interaction: two binding sites for small and large ligands as revealed by a combination of NMR spectroscopy and cross-linking mapping experiments.

Muñoz-García JC, Chabrol E, Vivès RR, Thomas A, de Paz JL, Rojo J, Imberty A, Fieschi F, Nieto PM, Angulo J.

J Am Chem Soc. 2015 Apr 1;137(12):4100-10. doi: 10.1021/ja511529x. Epub 2015 Mar 23.

PMID:
25747117
15.

Post-Synthetic Regulation of HS Structure: The Yin and Yang of the Sulfs in Cancer.

Vivès RR, Seffouh A, Lortat-Jacob H.

Front Oncol. 2014 Jan 14;3:331. doi: 10.3389/fonc.2013.00331. eCollection 2014 Jan 14. Review.

16.

Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan.

Delehedde M, Devenyns L, Maurage CA, Vivès RR.

Int J Cell Biol. 2013;2013:705027. doi: 10.1155/2013/705027. Epub 2013 Mar 28.

17.

HSulf sulfatases catalyze processive and oriented 6-O-desulfation of heparan sulfate that differentially regulates fibroblast growth factor activity.

Seffouh A, Milz F, Przybylski C, Laguri C, Oosterhof A, Bourcier S, Sadir R, Dutkowski E, Daniel R, van Kuppevelt TH, Dierks T, Lortat-Jacob H, Vivès RR.

FASEB J. 2013 Jun;27(6):2431-9. doi: 10.1096/fj.12-226373. Epub 2013 Mar 1.

PMID:
23457216
18.

Glycosaminoglycans are interactants of Langerin: comparison with gp120 highlights an unexpected calcium-independent binding mode.

Chabrol E, Nurisso A, Daina A, Vassal-Stermann E, Thepaut M, Girard E, Vivès RR, Fieschi F.

PLoS One. 2012;7(11):e50722. doi: 10.1371/journal.pone.0050722. Epub 2012 Nov 30.

19.

A New C-Xyloside induces modifications of GAG expression, structure and functional properties.

Vassal-Stermann E, Duranton A, Black AF, Azadiguian G, Demaude J, Lortat-Jacob H, Breton L, Vivès RR.

PLoS One. 2012;7(10):e47933. doi: 10.1371/journal.pone.0047933. Epub 2012 Oct 26.

20.

Factor h and properdin recognize different epitopes on renal tubular epithelial heparan sulfate.

Zaferani A, Vivès RR, van der Pol P, Navis GJ, Daha MR, van Kooten C, Lortat-Jacob H, Seelen MA, van den Born J.

J Biol Chem. 2012 Sep 7;287(37):31471-81. doi: 10.1074/jbc.M112.380386. Epub 2012 Jul 19.

21.

Transglutaminase-2 interaction with heparin: identification of a heparin binding site that regulates cell adhesion to fibronectin-transglutaminase-2 matrix.

Lortat-Jacob H, Burhan I, Scarpellini A, Thomas A, Imberty A, Vivès RR, Johnson T, Gutierrez A, Verderio EA.

J Biol Chem. 2012 May 25;287(22):18005-17. doi: 10.1074/jbc.M111.337089. Epub 2012 Mar 22.

22.

Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease.

Zaferani A, Vivès RR, van der Pol P, Hakvoort JJ, Navis GJ, van Goor H, Daha MR, Lortat-Jacob H, Seelen MA, van den Born J.

J Biol Chem. 2011 Feb 18;286(7):5359-67. doi: 10.1074/jbc.M110.167825. Epub 2010 Dec 6.

23.

Functional characterization of the recombinant human C1 inhibitor serpin domain: insights into heparin binding.

Rossi V, Bally I, Ancelet S, Xu Y, Frémeaux-Bacchi V, Vivès RR, Sadir R, Thielens N, Arlaud GJ.

J Immunol. 2010 May 1;184(9):4982-9. doi: 10.4049/jimmunol.0902016. Epub 2010 Mar 29.

24.

Heparan sulfate regulates ADAM12 through a molecular switch mechanism.

Sørensen HP, Vivès RR, Manetopoulos C, Albrechtsen R, Lydolph MC, Jacobsen J, Couchman JR, Wewer UM.

J Biol Chem. 2008 Nov 14;283(46):31920-32. doi: 10.1074/jbc.M804113200. Epub 2008 Sep 17.

25.

The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains, including the co-receptor binding site.

Crublet E, Andrieu JP, Vivès RR, Lortat-Jacob H.

J Biol Chem. 2008 May 30;283(22):15193-200. doi: 10.1074/jbc.M800066200. Epub 2008 Mar 31.

26.

Heparan sulphate proteoglycans and viral vectors : ally or foe?

Vivès RR, Lortat-Jacob H, Fender P.

Curr Gene Ther. 2006 Feb;6(1):35-44. Review.

PMID:
16475944
27.

Cellular uptake of the EBV transcription factor EB1/Zta.

Mahot S, Fender P, Vivès RR, Caron C, Perrissin M, Gruffat H, Sergeant A, Drouet E.

Virus Res. 2005 Jun;110(1-2):187-93.

PMID:
15845271
28.

Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site.

Vivès RR, Imberty A, Sattentau QJ, Lortat-Jacob H.

J Biol Chem. 2005 Jun 3;280(22):21353-7. Epub 2005 Mar 28.

29.

A novel strategy for defining critical amino acid residues involved in protein/glycosaminoglycan interactions.

Vivès RR, Crublet E, Andrieu JP, Gagnon J, Rousselle P, Lortat-Jacob H.

J Biol Chem. 2004 Dec 24;279(52):54327-33. Epub 2004 Oct 12.

30.
31.

A kinetics and modeling study of RANTES(9-68) binding to heparin reveals a mechanism of cooperative oligomerization.

Vivès RR, Sadir R, Imberty A, Rencurosi A, Lortat-Jacob H.

Biochemistry. 2002 Dec 17;41(50):14779-89.

PMID:
12475226
32.
34.

Sequence analysis of heparan sulphate and heparin oligosaccharides.

Vivès RR, Pye DA, Salmivirta M, Hopwood JJ, Lindahl U, Gallagher JT.

Biochem J. 1999 May 1;339 ( Pt 3):767-73.

35.

Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity.

Pye DA, Vives RR, Turnbull JE, Hyde P, Gallagher JT.

J Biol Chem. 1998 Sep 4;273(36):22936-42.

Supplemental Content

Loading ...
Support Center